α/β T‑cell/CD19 B‑cell depleted haploidentical HSCT carries the hope of making stem cell transplantation safer and more accessible, giving many patients a new chance for a lifesaving cure.

Join leading specialists from around the world to discuss the latest research and clinical breakthroughs related to T-cell depleted HSCT at this two-day, hybrid event held at Paul Berg Hall in the Li Ka Shing Learning and Knowledge Center (LKSC) on the Stanford School of Medicine campus and virtually. Our aim is to facilitate intellectual discussion and explore recent advancements in the field, with the hope of paving the way for future research and collaboration.

Our previous symposium attracted over 700 attendees from academia, biotech, pharma, and the non-profit sector. We expect an even wider audience to register and participate this year.

Speakers include:

• Selim Corbacioglu, MD, PhD, Regensburg, Bavaria, Germany
• Christopher Dvorak, MD, University of California, San Francisco
• Rupert Handgretinger, MD, PhD, Children’s University Hospital in Tuebingen, Germany
• Peter Lang, MD, PhD, University of Tubingen
• Richard O’Reilly, MD, Memorial Sloan Kettering Cancer Center
• Michael Allen Pulsipher, MD, University of Utah
• Bruno Silva Santos, PhD, University of Lisboa

The symposium is free and registration is now open. Plan to attend in person and join us for a wine and cheese reception after the event to network with fellow physician scientists, meet our sponsors and learn more about their newest technologies.

You are invited to submit both clinical and laboratory-based abstracts to the 2nd International Symposium on αβ T-cell/CD19 B-cell Depleted Haploidentical Stem Cell Transplantation, which will be a hybrid meeting held January 30-31, 2024, at Stanford University and virtually. 

Clinical abstracts focused on clinical outcomes, including the use of different conditioning regimens, incidence, and severity of GVHD or other complications such as graft failure, TMA, AHIA, etc. in both children and adults undergoing αβ T-cell/CD19 B-cell depleted haploidentical stem cell transplantation are encouraged. Enlighten us with stories of transformative patient care, therapeutic discoveries, unusual cases, or obstacles overcome in this intricate field. 

We also welcome laboratory-based abstracts highlighting novel insights gained through research on graft composition, post-HSCT immune reconstruction, and graft manufacturing processes. Contributions showcasing essential research on the basic science of αβ T-cell/CD19 B-cell depleted haploidentical stem cell transplantation can profoundly enrich the scientific community's understanding and knowledge in this field.

Abstract submission: Abstracts must be submitted by November 27th, 2023, at 11:59 PM PT. Multiple abstracts can be submitted.

Abstract specifications: The character limit for the body of the abstract is 2500 characters (approximately 300 words). The character count does not include spaces or the title but does include the space allocated to tables. The abstract may include up to 3 figures or images; the words within these are not deducted from the total character count. 

Notification: decisions on abstract acceptance/rejection will be made by the end of November 2023 and the decisions will be communicated by email.

Travel awards: We are offering two travel awards, each worth $1,000: one for the best clinical abstract, and one for the best laboratory abstract. The awards will support the transportation costs to permit the winning authors to present in person at the Symposium. 

The winners of the two $1,000 travel stipends will be notified by November 30th, 2023.